JonesTrading Keeps Their Buy Rating on Actinium Pharmaceuticals (ATNM)
12 Décembre 2022 - 05:05PM
TipRanks
JonesTrading analyst Justin Walsh maintained a Buy rating on
Actinium Pharmaceuticals (ATNM - Research Report) today and set a
price target of $24.00. The company's shares opened today at
$10.59.According to TipRanks, Walsh is an analyst with an average
return of -29.5% and a 21.21% success rate. Walsh covers the
Healthcare sector, focusing on stocks such as Actinium
Pharmaceuticals, Plus Therapeutics, and Lantheus.The word on The
Street in general, suggests a Strong Buy analyst consensus rating
for Actinium Pharmaceuticals with a $32.50 average price target,
implying a 206.89% upside from current levels. In a report released
today, H.C. Wainwright also reiterated a Buy rating on the stock
with a $53.
https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-actinium-pharmaceuticals-atnm?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2023 à Mar 2023
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023
